BTK Inhibitors Versus Venetoclax as First- or Second-Line Therapy in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Evidence Study

被引：0
|
作者：
Roeker, Lindsey E. [1 ]
Han, Yi [2 ]
Teschemaker, Anna [3 ]
Mato, Anthony R. [1 ]
Thompson, Meghan C. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA
[2] Vinzent Strategies, Blue Bell, PA USA
[3] AstraZeneca, Gaithersburg, MD USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2025年 / 100卷 / 04期
关键词：
Bruton tyrosine kinase inhibitor; chronic lymphocytic leukemia; real-world evidence; small lymphocytic lymphoma; venetoclax;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：720 / 723
页数：4
相关论文
共 50 条
  • [1] Real-world duration of venetoclax treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma
    Teschemaker, Anna
    Hakre, Shweta
    Tse, Jenny
    Shaikh, Nazneen Fatima
    Gu, Yifan
    Near, Aimee
    LEUKEMIA & LYMPHOMA, 2023, 64 : S62 - S63
  • [2] Real-world time to discontinuation of first-line venetoclax plus binutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma
    Lu, Xiaoxiao
    Emond, Bruno
    Qureshi, Zaina P.
    Wu, Linda H.
    Forbes, Shaun P.
    Hilts, Annalise
    Liu, Stephanie
    Lafeuille, Marie-Helene
    Lefebvre, Patrick
    Huang, Qing
    Rogers, Kerry A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2023,
  • [3] Real-world time to discontinuation of first-line venetoclax plus obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma
    Lu, Xiaoxiao
    Emond, Bruno
    Qureshi, Zaina P.
    Wu, Linda H.
    Forbes, Shaun P.
    Hilts, Annalise
    Liu, Stephanie
    Lafeuille, Marie-Helene
    Lefebvre, Patrick
    Huang, Qing
    Rogers, Kerry A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, : 1227 - 1235
  • [4] Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
    Lei, Matthew M.
    Sorial, Mark N.
    Lou, Uvette
    Yu, Michelle
    Medrano, Andrea
    Ford, Josie
    Nemec, Ronald A.
    Abramson, Jeremy S.
    Soumerai, Jacob D.
    LEUKEMIA & LYMPHOMA, 2024, 65 (05) : 653 - 659
  • [5] A Real-World Study of Zanubrutinib Treatment in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
    Zhu, Huayuan
    Xia, Yi
    Miao, Yi
    Qin, Shuchao
    Wu, Wei
    Qiu, Tonglu
    Wang, Li
    Fan, Lei
    Xu, Wei
    Li, Jianyong
    BLOOD, 2023, 142
  • [6] Real-world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience
    Laurenti, Luca
    Scarfo, Lydia
    Frustaci, Anna Maria
    Sanna, Alessandro
    Iannella, Emilia
    Caira, Morena
    Finsinger, Paola
    Schifano, Silvia
    Neri, Benedetta
    Molica, Stefano
    Mauro, Francesca Romana
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (04) : 621 - 630
  • [7] Real-world outcomes after discontinuation of covalent BTK inhibitor-based therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
    Jain, Nitin
    Eyre, Toby A.
    Winfree, Katherine B.
    Bhandari, Naleen Raj
    Khanal, Manoj
    Sugihara, Tomoko
    Chen, Yongmei
    Abada, Paolo
    Patel, Krish
    LEUKEMIA & LYMPHOMA, 2025,
  • [8] Real World Comparison of Bruton Tyrosine Kinase Inhibitors and Venetoclax in Patients Diagnosed with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Roeker, Lindsey E.
    Han, Yi
    Ryan, Kellie J.
    Teschemaker, Anna
    Mato, Anthony R.
    BLOOD, 2022, 140 : 7025 - 7027
  • [9] Real-World Effectiveness and Safety Outcomes of Acalabrutinib Treatment By Line of Therapy in Patients with Chronic Lymphocytic Leukemia and/or Small Lymphocytic Lymphoma
    Jacobs, Ryan W.
    Teschemaker, Anna
    Hakre, Shweta
    Tian, Hongping
    Pyrih, Nick
    Wahlstrom, Svea K.
    Cui, Lianzhou
    BLOOD, 2023, 142
  • [10] Real-world outcomes of venetoclax and rituximab for chronic lymphocytic leukemia/small lymphocytic lymphoma: A retrospective analysis of nine Japanese cases
    Saburi, Masuho
    Nishikawa, Takumi
    Miyazaki, Yasuhiko
    Kohno, Kazuhiro
    Sakata, Masanori
    Okuhiro, Kazuki
    Nakayama, Toshiyuki
    Ohtsuka, Eiichi
    Ogata, Masao
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2024, 64 (02) : 152 - 155
12345